1Simonet WS, Lacey DL, Dunstan CR, et al. Oaeoprotegerin: a novel secreted pro- tein involved in the regulation of bone density [J]. Cell, 1997, 89 (2): 309-319.
2Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor [J]. J Biol Chem, 1998, 273 (9): 5117 - 5123.
3Vidal NO, Brandstrom H, Jonsson KB, et al. Osteoprotegerin mRNA is expressed in primary human osteoblast - like cells: down -regulation by glucocorticoids [J]. J Endocrinol, 1998, 159 (1): 191 - 195.
4Lacey DL, Timms E, Tan HL, el al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J]. Cell, 1998, 93 (2): 165-176.
5Nakashiraa T, Wada T, Penninger JM. RANKI, and RANK as novel therapeutic tar- gets for arthritis [ J ]. Curr Opin Rheumatol, 2003, 15: 280-287.
6Sato K, Takayanagi H. Osteoclasts,rheumatoid arthritis, and osteoimmunology [J]. Cure Opin Rheumatol, 2006, 18: 419 - 426.
8Hofbauer LC, Schoppet M, Christ M, et al. Ttunour necrosis factorrelated apoptosis- inducing ligand and osteoprotegerin serum levels in psoriatic arthritis [ J ]. Rheuroatology, 2006, 45: 1218-1222.
9Kim HR,Kim HY, Lee SH. Elevated serum levels of ,soluble receptor activator of nuclear factors -kB ligand (sRANKL) and reduced bone mineral density in patients with ankylosingspondylitis (AS) [J]. Rlleumatology 2006, 45: 1197-1200.
10Lubberts E, Oppers - Walgreen B, Pettit AR, et al. Increase in expression of receptor activator of nuclear factor kB at sites of bone erosion correlates with progression of inflammation in evolving collageninduced arthritis [ J ]. Arthritis Rheum, 2002, 46 (11): 3055-3064.
同被引文献19
1Aoki A, Kojima F, Uchida K, et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients[J]. Geriatr Gerontol Int, 2009, 9(3): 246-252.
2Adragao T, Herberth J, Monier-Faugere MC, et al. Low bone volume-a risk factor for coronary calcifications in hemodialysis patients[J]. Clin J Am Soc Nephrol, 2009, 4(2): 450-455.
3Aoyagi K, Ross PD, Orloff J, et al. Low bone density is not associated with aortic calcification[J]. Calcif Tissue Int, 2001, 69(1): 20-24.
4Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification[J]. Genes Dev, 1998, 12(9): 1260-1268.
5Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients[J]. Nephrol Dial Transplant, 2004, 19(6): 1480-1488.
6Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell, 1997, 89(2): 309-319.
7Tousoulis D, Siasos G, Maniatis K, et al. Novel biomarkers assessing the calcium deposition in coronary artery disease[J]. Curr Med Chem, 2012, 19(6): 901-920.
9Bekker P J, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women[J]. J Bone Miner Res, 2001, 16(2): 348-360.
10Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway[J]. Circ Res, 2009, 104(9): 1041-1048.
